肿瘤相关静脉血栓栓塞症防治基石——抗凝药物应用进展

doi:10.3969/j.issn.1006-5725.2025.05.022

Abstract

Abstract:

Cancer-associated venous thromboembolism （CAT） refers to the presence of venous thromboembolism including deep vein thrombosis and pulmonary embolism in patients with malignant cancer. Studies have indicated that CAT has become the second leading cause of death among cancer patients. Similar to other methods used to prevent and treat venous thromboembolism， anticoagulation remains to be the primary approach for CAT. However， the occurrence of CAT is influenced by various factors such as tumor type， staging， complications， treatment， and prognosis. This complexity makes the prevention and management of CAT more difficult and challenging. This article reviews the classification of commonly used anticoagulant drugs in clinical practice， emphasizing the current status and advancements in their application for the prevention and treatment of cancer-related venous thromboembolism in order to provide valuable reference for clinical medication.

Key words: cancer-associated venous thromboembolism, anticoagulant drugs, heparin, low molecular weight heparin, new anticoagulants

CLC Number:

R730.6

Xiaoli QIN,Xiurong GAO,Qin HE,Zhumei LUO,Qian. JIANG. Research progress on role of anticoagulant drugs in prevention and treatment of cancer⁃associated venous thromboembolism[J]. The Journal of Practical Medicine, 2025, 41(5): 766-772.

References 63

1	韩静，常延河，刘运秋，等. 延展期抗凝和标准抗凝治疗特发性静脉血栓栓塞性疾病疗效对比［J］. 实用医学杂志， 2023，39（13）：1663-1668.
2	HARRIGAN A M， RIOUX J， SHIVAKUMAR S. Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism： A Guide for the General Oncology Practitioner［J］. Curr Oncol， 2022，29（9）：6419-6432. doi:10.3390/curroncol29090505 doi: 10.3390/curroncol29090505
3	VEDOVATI M C， GIUSTOZZI M， BECATTINI C. Venous thromboembolism and cancer： Current and future role of direct-acting oral anticoagulants［J］. Thromb Res， 2019，177：33-41. doi:10.1016/j.thromres.2019.02.031 doi: 10.1016/j.thromres.2019.02.031
4	黄菊，邵群. 肿瘤相关静脉血栓栓塞症的预防与治疗进展［J］. 中华医学杂志， 2024，104（2）：152-157.
5	陈诗雨，罗专波. 肿瘤相关静脉血栓栓塞症研究进展［J］. 临床荟萃， 2024，39（4）：363-369.
6	HAO C， SUN M， WANG H， et al. Low molecular weight heparins and their clinical applications［J］. Prog Mol Biol Transl Sci， 2019，163：21-39. doi:10.1016/bs.pmbts.2019.02.003 doi: 10.1016/bs.pmbts.2019.02.003
7	朱依谆. 药理学［M］. 北京：人民卫生出版社， 2019：390-393.
8	李家泰. 临床药理学［M］. 3版. 北京：人民卫生出版社， 2007：1562-1564.
9	李萍，李明春，王春燕. 抗凝药物预防与治疗肿瘤患者静脉血栓栓塞症的研究进展［J］. 中国药房， 2020，31（23）：2932-2937.
10	RUNGJIRAJITTRANON T， OWATTANAPANICH W， CHINTHAMMITR Y， et al. Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer： A systematic review and meta-analysis［J］. Thromb J， 2022，20（1）：41. doi:10.1186/s12959-022-00399-7 doi: 10.1186/s12959-022-00399-7
11	STREIFF M B， HOLMSTROM B， ANGELINI D， et al. Cancer-Associated Venous Thromboembolic Disease， Version 2.2021， NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw， 2021，19（10）：1181-1201.
12	陈永法，韩洪娜. 达比加群和利伐沙班及华法林预防心房颤动并发脑卒中的经济学评价［J］. 中国新药杂志， 2016，25（11）：1216-1224.
13	KHORANA A A， NOBLE S， LEE A， et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism： Guidance from the SSC of the ISTH［J］. J Thromb Haemost， 2018，16（9）：1891-1894. doi:10.1111/jth.14219 doi: 10.1111/jth.14219
14	RASKOB G E， VAN ES N， VERHAMME P， et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism［J］. N Engl J Med， 2018，378（7）：615-624. doi:10.1056/nejmoa1711948 doi: 10.1056/nejmoa1711948
15	李雪梅，聂晓红，向莉莉，等. 磺达肝癸钠与依诺肝素钠预防肺血栓栓塞症对比研究［J］. 实用医学杂志， 2022，38（17）：2216-2220.
16	SUN Z G， YANG-LIU， ZHANG J M， et al. The Research Progress of Direct Thrombin Inhibitors［J］. Mini Rev Med Chem， 2020，20（16）：1574-1585. doi:10.2174/1389557519666191015201125 doi: 10.2174/1389557519666191015201125
17	张嘉俊，杨琰茗，杨雅清，等. Ⅹa因子抑制剂预防和治疗癌症患者静脉血栓栓塞有效性和安全性的Meta分析［J］. 中国药房， 2020，31（6）：729-733.
18	马军，秦叔逵，吴一龙，等. 肿瘤相关静脉血栓栓塞症预防与治疗指南（2019版）［J］. 中国肿瘤临床， 2019，46（13）：653-660.
19	CARRIER M， KHORANA A A， MORETTO P， et al. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer［J］. Am J Med， 2014，127（1）：82-86. doi:10.1016/j.amjmed.2013.09.015 doi: 10.1016/j.amjmed.2013.09.015
20	BARBAR S， ROSSETTO V， PRANDONI P. Thromboprophylaxis in medical inpatients with cancer［J］. Am J Med， 2014，127（10）：e11. doi:10.1016/j.amjmed.2014.05.017 doi: 10.1016/j.amjmed.2014.05.017
21	KHORANA A A， SOFF G A， KAKKAR A K， et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer［J］. N Engl J Med， 2019，380（8）：720-728. doi:10.1056/nejmoa1814630 doi: 10.1056/nejmoa1814630
22	WANG T F， ZWICKER J I， AY C， et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients： Guidance from the SSC of the ISTH［J］. J Thromb Haemost， 2019，17（10）：1772-1778. doi:10.1111/jth.14564 doi: 10.1111/jth.14564
23	LEE A Y， LEVINE M N， BAKER R I， et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer［J］. N Engl J Med， 2003，349（2）：146-153. doi:10.1056/nejmoa025313 doi: 10.1056/nejmoa025313
24	LEE A， KAMPHUISEN P W， MEYER G， et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer： A Randomized Clinical Trial［J］. JAMA， 2015，314（7）：677-686. doi:10.1001/jama.2015.9243 doi: 10.1001/jama.2015.9243
25	AKL E A， KAHALE L， BARBA M， et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer［J］. Cochrane Database Syst Rev， 2014（7）：CD6650.
26	PRINS M H， LENSING A W， BRIGHTON T A， et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer （EINSTEIN-DVT and EINSTEIN-PE）： A pooled subgroup analysis of two randomised controlled trials［J］. Lancet Haematol， 2014，1（1）：e37-e46. doi:10.1016/s2352-3026(14)70018-3 doi: 10.1016/s2352-3026(14)70018-3
27	SCHULMAN S， GOLDHABER S Z， KEARON C， et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer［J］. Thromb Haemost， 2015，114（1）：150-157. doi:10.1160/th14-11-0977 doi: 10.1160/th14-11-0977
28	AGNELLI G， BULLER H R， COHEN A， et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients： Results from the AMPLIFY trial［J］. J Thromb Haemost， 2015，13（12）：2187-2191. doi:10.1111/jth.13153 doi: 10.1111/jth.13153
29	VEDOVATI M C， GERMINI F， AGNELLI G， et al. Direct oral anticoagulants in patients with VTE and cancer： A systematic review and meta-analysis［J］. Chest， 2015，147（2）：475-483. doi:10.1378/chest.14-0402 doi: 10.1378/chest.14-0402
30	ROSSEL A， ROBERT-EBADI H， COMBESCURE C， et al. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients： A systematic review and network meta-analysis［J］. PLoS One， 2019，14（3）：e213940. doi:10.1371/journal.pone.0213940 doi: 10.1371/journal.pone.0213940
31	RASKOB G E， VAN ES N， SEGERS A， et al. Edoxaban for venous thromboembolism in patients with cancer： Results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised， double-blind， double-dummy trial［J］. Lancet Haematol， 2016，3（8）：e379-e387. doi:10.1016/s2352-3026(16)30057-6 doi: 10.1016/s2352-3026(16)30057-6
32	GIUSTOZZI M， FRANCO L， AGNELLI G， et al. Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism［J］. Trends Cardiovasc Med， 2023，33（6）：336-343. doi:10.1016/j.tcm.2022.02.003 doi: 10.1016/j.tcm.2022.02.003
33	RASKOB G E， BULLER H R， SEGERS A. Edoxaban for Cancer-Associated Venous Thromboembolism［J］. N Engl J Med， 2018，379（1）：95-96. doi:10.1056/nejmc1806646 doi: 10.1056/nejmc1806646
34	YOUNG A M， MARSHALL A， THIRLWALL J， et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism： Results of a Randomized Trial （SELECT-D）［J］. J Clin Oncol， 2018，36（20）：2017-2023.
35	LI A， GARCIA D A， LYMAN G H， et al. Direct oral anticoagulant （DOAC） versus low-molecular-weight heparin （LMWH） for treatment of cancer associated thrombosis （CAT）： A systematic review and meta-analysis［J］. Thromb Res， 2019，173：158-163. doi:10.1016/j.thromres.2018.02.144 doi: 10.1016/j.thromres.2018.02.144
36	AGNELLI G， BECATTINI C， MEYER G， et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer［J］. N Engl J Med， 2020，382（17）：1599-1607. doi:10.1056/nejmoa1915103 doi: 10.1056/nejmoa1915103
37	MCBANE R N， WYSOKINSKI W E， LE-RADEMACHER J G， et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism： The ADAM VTE trial［J］. J Thromb Haemost， 2020，18（2）：411-421.
38	LYMAN G H， CARRIER M， AY C， et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism： prevention and treatment in patients with cancer［J］. Blood Adv， 2021，5（4）：927-974. doi:10.1182/bloodadvances.2021004734 doi: 10.1182/bloodadvances.2021004734
39	STEVENS S M， WOLLER S C， KREUZIGER L B， et al. Antithrombotic Therapy for VTE Disease： Second Update of the CHEST Guideline and Expert Panel Report［J］. Chest， 2021，160（6）：e545-e608. doi:10.1016/j.chest.2021.07.055 doi: 10.1016/j.chest.2021.07.055
40	JARA-PALOMARES L， SOLIER-LOPEZ A， ELIAS-HERNANDEZ T， et al. Tinzaparin in cancer associated thrombosis beyond 6months： TiCAT study［J］. Thromb Res， 2017，157：90-96. doi:10.1016/j.thromres.2017.07.004 doi: 10.1016/j.thromres.2017.07.004
41	FARGE D， FRERE C， CONNORS J M， et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer， including patients with COVID-19［J］. Lancet Oncol， 2022，23（7）：e334-e347.
42	KEY N S， KHORANA A A， KUDERER N M， et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer： ASCO Guideline Update［J］. J Clin Oncol， 2023，41（16）：3063-3071. doi:10.1200/jco.23.00294 doi: 10.1200/jco.23.00294
43	MAHE I， AGNELLI G， AY C， et al. Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism： Rationale and Design of the API-CAT Study［J］. Thromb Haemost， 2022，122（4）：646-656. doi:10.1055/a-1647-9896 doi: 10.1055/a-1647-9896
44	IBRAHIM R B， SKEWES M D， KURIAKOSE P. 'Sailing in troubled waters'： A review of the use of anticoagulation in adult cancer patients with thrombocytopenia［J］. Blood Coagul Fibrinolysis， 2016，27（6）：615-630. doi:10.1097/mbc.0000000000000539 doi: 10.1097/mbc.0000000000000539
45	KHANAL N， BOCIEK R G， CHEN B， et al. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia［J］. Am J Hematol， 2016，91（11）：E468-E472. doi:10.1002/ajh.24526 doi: 10.1002/ajh.24526
46	SAMUELSON B B， LEE A， KHORANA A A， et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia： A systematic review［J］. Res Pract Thromb Haemost， 2018，2（4）：664-669. doi:10.1002/rth2.12111 doi: 10.1002/rth2.12111
47	CARRIER M， KHORANA A A， ZWICKER J， et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding： guidance from the SSC of the ISTH［J］. J Thromb Haemost， 2013，11（9）：1760-1765. doi:10.1111/jth.12338 doi: 10.1111/jth.12338
48	JO J T， SCHIFF D， PERRY J R. Thrombosis in brain tumors［J］. Semin Thromb Hemost， 2014，40（3）：325-331. doi:10.1055/s-0034-1370791 doi: 10.1055/s-0034-1370791
49	JENKINS E O， SCHIFF D， MACKMAN N， et al. Venous thromboembolism in malignant gliomas［J］. J Thromb Haemost， 2010，8（2）：221-227. doi:10.1111/j.1538-7836.2009.03690.x doi: 10.1111/j.1538-7836.2009.03690.x
50	MARRAS L C， GEERTS W H， PERRY J R. The risk of venous thromboembolism is increased throughout the course of malignant glioma： An evidence-based review［J］. Cancer， 2000，89（3）：640-646. doi:10.1002/1097-0142(20000801)89:3<640::aid-cncr20>3.0.co;2-e doi: 10.1002/1097-0142(20000801)89:3<640::aid-cncr20>3.0.co;2-e
51	ZWICKER J I， KARP L R， CARRIER M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation［J］. J Thromb Haemost， 2016，14（9）：1736-1740. doi:10.1111/jth.13387 doi: 10.1111/jth.13387
52	PORFIDIA A， GIORDANO M， STURIALE C L， et al. Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism： A meta-analysis［J］. Brain Behav， 2020，10（6）：e1638. doi:10.1002/brb3.1638 doi: 10.1002/brb3.1638
53	CARNEY B J， UHLMANN E J， PULIGANDLA M， et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors［J］. J Thromb Haemost， 2019，17（1）：72-76. doi:10.1111/jth.14336 doi: 10.1111/jth.14336
54	DEBOURDEAU P， FARGE D， BECKERS M， et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer［J］. J Thromb Haemost， 2013，11（1）：71-80. doi:10.1111/jth.12071 doi: 10.1111/jth.12071
55	ZWICKER J I， CONNOLLY G， CARRIER M， et al. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients： guidance from the SSC of the ISTH［J］. J Thromb Haemost， 2014，12（5）：796-800. doi:10.1111/jth.12527 doi: 10.1111/jth.12527
56	BAUMANN K L， GADDH M， ONADEKO O， et al. Treatment of catheter-related thrombosis in patients with hematologic malignancies： A Venous thromboEmbolism Network U.S. retrospective cohort study［J］. Thromb Res， 2021，202：155-161. doi:10.1016/j.thromres.2021.03.021 doi: 10.1016/j.thromres.2021.03.021
57	LAUBE E S， MANTHA S， SAMEDY P， et al. Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban［J］. Am J Hematol， 2017，92（1）：E9-E10. doi:10.1002/ajh.24588 doi: 10.1002/ajh.24588
58	DAVIES G A， LAZO-LANGNER A， GANDARA E， et al. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients （Catheter 2）［J］. Thromb Res， 2018，162：88-92. doi:10.1016/j.thromres.2017.04.003 doi: 10.1016/j.thromres.2017.04.003
59	TUFANO A， AGENO W， DI MICCO P， et al. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis［J］. Thromb Res， 2018，164：69-74. doi:10.1016/j.thromres.2018.02.143 doi: 10.1016/j.thromres.2018.02.143
60	AGENO W， BEYER-WESTENDORF J， GARCIA D A， et al. Guidance for the management of venous thrombosis in unusual sites［J］. J Thromb Thrombolysis， 2016，41（1）：129-143. doi:10.1007/s11239-015-1308-1 doi: 10.1007/s11239-015-1308-1
61	GIUSTOZZI M， CURCIO A， WEIJS B， et al. Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer［J］. Thromb Haemost， 2020，120（5）：847-856. doi:10.1055/s-0040-1709527 doi: 10.1055/s-0040-1709527
62	HORSTED F， WEST J， Grainge M J. Risk of venous thromboembolism in patients with cancer： A systematic review and meta-analysis［J］. PLoS Med， 2012，9（7）：e1001275. doi:10.1371/journal.pmed.1001275 doi: 10.1371/journal.pmed.1001275
63	孙红娜，郑玉粉，于锋. 新型口服抗凝药的药物相互作用［J］.中国医院药学杂志，2021，41（3）：314-320.

[1]	SUN Zhihong. . Effect of flurbiprofen axetil combined with low molecular weight heparin on VAS score and oxidative stress response in elderly patients with hip replacement [J]. The Journal of Practical Medicine, 2023, 39(13): 1693-1697.
[2]	ZHANG Chunling, YANG Yuanjian, LIU Chang, ZHANG Weihua.. Clinical significance of serum PCT，BBP，IL⁃6 combined SOFA score in prognosis assessment of patients with severe pneumonia [J]. The Journal of Practical Medicine, 2022, 38(2): 168-172.
[3]	LIANG Wenmei, FU Bao, ZHAO Xiaoyu, SU De, DAI Dahua, GONG Minmin, FU Xiaoyun. . Effects of Xuebijing Injection combined with low molecular weight heparin on PTX3 and HPSE levels in elderly patients with acute respiratory distress syndrome [J]. The Journal of Practical Medicine, 2022, 38(14): 1814-1818.
[4]	YANG Yang, SONG Xinye, LUAN Yong. Effect of different ratios of protamine to neutralizing heparin on bleeding and clotting after cardiopulmo⁃nary bypass using thromboelastography [J]. The Journal of Practical Medicine, 2020, 36(21): 2926-2930.

Research progress on role of anticoagulant drugs in prevention and treatment of cancer⁃associated venous thromboembolism

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 63

Related Articles 4

Recommended Articles

Metrics

Comments